NMTR Key Statistics, Chart & Performance
The current stock price of NMTR is 0.0722 USD. In the past month the price decreased by -88.9%. In the past year, price decreased by -98.36%.
NMTR Latest News, Press Relases and Analysis
NMTR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 50.22 | 1.05T | ||
| JNJ | JOHNSON & JOHNSON | 20 | 499.88B | ||
| MRK | MERCK & CO. INC. | 11.88 | 261.34B | ||
| PFE | PFIZER INC | 8.03 | 146.18B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.51 | 100.25B | ||
| ZTS | ZOETIS INC | 20.14 | 56.59B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.69 | 23.23B | ||
| VTRS | VIATRIS INC | 4.57 | 12.40B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.28 | 11.58B | ||
| CORT | CORCEPT THERAPEUTICS INC | 90.68 | 8.39B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.53B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.52B |
Related stock screener links
About NMTR
Company Profile
9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on unmet needs in gastroenterology. The company is headquartered in Raleigh, North Carolina and currently employs 10 full-time employees. The company went IPO on 2016-07-08. The firm is engaged in developing novel treatments for people with rare digestive diseases, gastrointestinal (GI) conditions with unmet needs, and debilitating disorders in which the biology of the gut is a contributing factor. The firm is developing vurolenatide, a proprietary long-acting GLP-1 agonist in Phase 3 development for short bowel syndrome as well as near clinical-stage assets including NM-136 for obesity disorders. The long-acting linker technology is designed specifically to address the gastric effects in SBS patients by slowing digestive transit time. Vurolenatide uses proprietary XTEN technology to extend the half-life of exenatide, potentially allowing for every other week dosing (Q2W). NM-136 is a long-acting, highly specific, humanized anti-GIP monoclonal antibody.
Company Info
9 METERS BIOPHARMA INC
4509 Creedmoor Road, Suite 600
Raleigh NORTH CAROLINA 27615 US
CEO: John Temperato
Employees: 10
Phone: 19192751933.0
9 METERS BIOPHARMA INC / NMTR FAQ
What does 9 METERS BIOPHARMA INC do?
9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on unmet needs in gastroenterology. The company is headquartered in Raleigh, North Carolina and currently employs 10 full-time employees. The company went IPO on 2016-07-08. The firm is engaged in developing novel treatments for people with rare digestive diseases, gastrointestinal (GI) conditions with unmet needs, and debilitating disorders in which the biology of the gut is a contributing factor. The firm is developing vurolenatide, a proprietary long-acting GLP-1 agonist in Phase 3 development for short bowel syndrome as well as near clinical-stage assets including NM-136 for obesity disorders. The long-acting linker technology is designed specifically to address the gastric effects in SBS patients by slowing digestive transit time. Vurolenatide uses proprietary XTEN technology to extend the half-life of exenatide, potentially allowing for every other week dosing (Q2W). NM-136 is a long-acting, highly specific, humanized anti-GIP monoclonal antibody.
Can you provide the latest stock price for 9 METERS BIOPHARMA INC?
The current stock price of NMTR is 0.0722 USD. The price decreased by -42.97% in the last trading session.
What is the dividend status of 9 METERS BIOPHARMA INC?
NMTR does not pay a dividend.
What is the ChartMill technical and fundamental rating of NMTR stock?
NMTR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
How many employees does 9 METERS BIOPHARMA INC have?
9 METERS BIOPHARMA INC (NMTR) currently has 10 employees.
What is 9 METERS BIOPHARMA INC worth?
9 METERS BIOPHARMA INC (NMTR) has a market capitalization of 1.04M USD. This makes NMTR a Nano Cap stock.
Can you provide the ownership details for NMTR stock?
You can find the ownership structure of 9 METERS BIOPHARMA INC (NMTR) on the Ownership tab.
NMTR Technical Analysis
NMTR Financial Highlights
Over the last trailing twelve months NMTR reported a non-GAAP Earnings per Share(EPS) of -3.46. The EPS decreased by -8.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NMTR Forecast & Estimates
11 analysts have analysed NMTR and the average price target is 10.58 USD. This implies a price increase of 14557.2% is expected in the next year compared to the current price of 0.0722.